A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With DocetaxelPierre Maison‐Blanche, E. Magherini, Sanjiv S. Agarwala et al.|Journal of Cardiovascular Pharmacology|2013Cited by 5
LAPACT: An open-label, multicenter phase II trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).Philip Agop Philip, Pascal Hammel, Jill Lacy et al.|Journal of Clinical Oncology|2016Cited by 3